BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-92@pharmaconomics
DTSTAMP:20260707T014110Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:BNTX Phase 2 — BNT327 Dose Level 1 (DL1) (estimated date)
DESCRIPTION:Phase 2 trial results for BNT327 Dose Level 1 (DL1) in Extensive-stage Small-cell Lung Cancer are due ~ Jun 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06449209\n\nTrack it: https://pharmaconomics.com/e/92
URL:https://pharmaconomics.com/e/92
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BNTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR